ProKidney Announces Pricing of its Upsized $130 Million globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
WINSTON-SALEM, N.C., June 11, 2024 ProKidney Corp. , a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, today announced the pricing of an.
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
ProKidney (NASDAQ:PROK – Free Report) had its price objective boosted by Bank of America from $3.00 to $4.00 in a research note issued to investors on Wednesday morning, Benzinga reports. Bank of America currently has a neutral rating on the stock. Separately, Morgan Stanley began coverage on ProKidney in a report on Thursday, March 7th. […]